Full-Time

Medical Director/Senior Medical Director

Confirmed live in the last 24 hours

Voyager Therapeutics

Voyager Therapeutics

201-500 employees

Develops genetic medicines for neurological diseases

Biotechnology
Healthcare

Senior

Lexington, MA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • M.D. with deep Neuroscience experience
  • 3+ years’ experience in clinical development within a biotech or pharmaceutical company
  • Experience in neurology clinical development is required and experience in neuromuscular diseases and/or dementia is optimal
  • Experience in gene therapy drug development, RNA, nucleotide, and/or gene editing experience considered a plus
  • Experience working collaboratively within a multi-disciplinary team of colleagues and proven ability to interact with external experts and investigators
  • Adaptability, flexibility, independence, and resourcefulness to roll-up-sleeves and multi-task to thrive in a small company
  • Experience in early-stage development programs
  • Demonstrated command working with FDA, MHRA and ICH GCP guidelines to ensure the appropriate conduct of clinical studies
  • Effective oral and written communication skills are required, as are excellent interpersonal skills with demonstrated ability to work with a small growing team. Marked proficiency in clinical/medical writing
  • Integrity, honesty and highest ethical standards and a sense of personal accountability
Responsibilities
  • Contribute to the development and execution of comprehensive clinical development plans for Voyager’s development programs. Offer expert clinical advice, drawing on extensive clinical knowledge. Provide feedback on clinical study data, reports, protocols, and development plans. Collaborate with early development research teams on clinical aspects and disease indications
  • Serve as a medical expert in the company, staying current with the latest research and medical advancements in the fields being studied
  • Contribute to the design and oversight of clinical trials, develop study protocols, case report forms, and informed consent documents, ensuring they are conducted in compliance with regulatory standards and ethical guidelines
  • Collaborate with the regulatory team to prepare and submit regulatory documents to health authorities, including INDs, NDAs, and BLAs. Collaborate with study team to prepare and complete clinical study reports, investigator’s brochures
  • Provide medical oversight for future clinical trials, including safety monitoring, data analysis, and interpretation of clinical trial results
  • Build and maintain strong relationships with key opinion leaders (KOLs) and academic institutions to support the company's scientific and clinical objectives
  • Collaborate closely with other departments such as clinical operations, technical operations/CMC, translational research and regulatory affairs to ensure alignment on program objectives
  • Lead the development of scientific publications, presentations, and educational materials related to Voyager’s programs

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary AAV (adeno-associated virus) capsid discovery platform, which allows for the delivery of genetic material directly to the brain through intravenous dosing. This method addresses the challenge of crossing the blood-brain barrier, which is crucial for effective treatment of brain-related conditions. Unlike many competitors, Voyager Therapeutics emphasizes collaboration with larger pharmaceutical companies to enhance their research and development efforts, which helps them accelerate the creation and commercialization of new therapies. The company's goal is to provide meaningful treatments that improve the lives of patients suffering from severe neurological disorders.

Company Stage

IPO

Total Funding

$102.1M

Headquarters

Cambridge, Massachusetts

Founded

2014

Growth & Insights
Headcount

6 month growth

3%

1 year growth

11%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Electric pulse technology could enhance Voyager's gene therapy delivery efficiency and outcomes.
  • FDA's gene therapy approval for sickle cell may benefit Voyager's CNS therapy pipeline.
  • Voyager's Novartis deal provides resources and expertise for accelerated gene therapy development.

What critics are saying

  • Competition from electric pulse gene therapy methods could impact Voyager's market share.
  • New CMO Toby Ferguson's appointment may disrupt ongoing projects with strategic shifts.
  • Reliance on milestone payments could lead to financial instability if milestones aren't met.

What makes Voyager Therapeutics unique

  • Voyager focuses on CNS diseases needing new therapies, like Parkinson's and ALS.
  • Their proprietary AAV capsid platform enables gene delivery across the blood-brain barrier.
  • Voyager's collaboration model accelerates development through partnerships with major pharmaceutical companies.

Help us improve and share your feedback! Did you find this helpful?